Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-03-06 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于2020年限制性股票激励计划授予第二个归属期第一批次归属结果暨股份上市公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the granting and listing of restricted stock under a 2020 restricted stock incentive plan. It details the number of shares granted, the decision-making process, the listing date, and the impact on share capital. It includes references to board meetings, shareholder meetings, and regulatory compliance but does not contain financial statements or detailed financial performance data. The document length is under 5,000 characters and primarily serves as a formal announcement of stock incentive plan share vesting and listing. Therefore, it is not a full financial report or management discussion but an announcement related to share issuance and capital changes. The most appropriate classification is Share Issue/Capital Change (SHA).
2023-03-06 Chinese
关于董事辞任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company director, Mr. Tian Lixin, from the board of Shenzhen Microchip Biotechnology Co., Ltd. It includes references to company law and stock exchange listing rules, and confirms that the resignation will not affect the board's legal operation. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-02-27 Chinese
关于微芯新域与百奥赛图全资子公司祐和医药签署独家许可协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Microchip Biotech Co., Ltd. regarding the signing of an exclusive license agreement between its subsidiary and another company's subsidiary for a new drug. It details the transaction terms, parties involved, and potential impacts and risks. The content focuses on a capital/financing update related to licensing and milestone payments, not a full financial report or earnings release. The document length is 3392 characters, which is relatively short but contains substantive transaction details rather than just a notice of report publication. There is no indication of it being an annual or interim report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-02-27 Chinese
2022年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled '2022 年度业绩快报公告' which translates to '2022 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2022, including revenue, profit, and other financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be in the company's 2022 Annual Report. The document is relatively short (1649 characters) and serves as a quick earnings update rather than a full comprehensive report. It does not contain full financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of a report publication but a brief financial performance summary. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2022
2023-02-27 Chinese
关于作废部分已授予尚未归属的2020年第二个归属期限制性股票的公告
Board/Management Information Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the cancellation of part of the 2020 restricted stock awards that have been granted but not yet vested. It details the decision-making process, approvals, and legal opinions related to this cancellation. The content focuses on corporate governance matters related to stock incentive plans and does not contain financial statements or quarterly/yearly financial results. It is not a full annual or interim report, nor an earnings release. It is also not a proxy solicitation or voting results announcement. The document is a formal announcement about a management decision concerning stock incentives, which fits best under Board/Management Information (MANG) as it relates to board decisions and management actions on equity incentives.
2023-02-09 Chinese
监事会关于2020年限制性股票第二个归属期归属名单、2021年限制性股票第一个归属期归属名单和2021年股票增值权第一个行权期行权名单的核查意见
Regulatory Filings Classification · 85% confidence The document is a formal opinion from the Supervisory Board of Shenzhen Microchip Biotechnology Co., Ltd. regarding the verification of the restricted stock incentive plans' vesting lists and stock appreciation rights exercise lists for specific periods in 2020 and 2021. It references compliance with company law, securities law, stock exchange listing rules, and internal governance documents. The content focuses on the approval and verification of stock incentive plan participants and their vesting or exercise of stock rights. This type of document is related to insider share transactions or equity incentive plans but is not a direct report of share transactions by directors (which would be DIRS). It is also not a general regulatory filing or announcement but a supervisory board opinion on stock incentive matters. Given the nature of the document, it best fits under Regulatory Filings (RNS) as it does not match other more specific categories like Director's Dealing or Share Issue/Capital Change, and it is not a full report or announcement of financial results or governance changes. The document length is short (1772 characters), and it is a formal verification opinion rather than a report or announcement of a meeting or vote.
2023-02-09 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.